Drug intelligence / Profile preview

Debio 1454

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Debio 1454 is an investigational, pathogen‑specific antibiotic being developed by Debiopharm for the treatment of infections caused by multidrug‑resistant Acinetobacter baumannii, particularly hospital‑acquired pneumonia. It belongs to a new class of FabI (enoyl‑acyl carrier protein reductase) inhibitors that block bacterial fatty acid biosynthesis, an essential pathway for cell membrane and cell wall formation, leading to bacterial cell death while aiming to spare the commensal microbiome and reduce selection for resistance.[5][13]

Targets

InhA

Beyond the preview

Go deeper on Debio 1454.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1454.

Explore the full profile